4-1BB Ligand/TNFSF9 Antibody (2357C) [Unconjugated]

4‑1BB Ligand/TNFSF9 was detected in immersion fixed paraffin-embedded sections of human Crohn's disease intestine using Rabbit Anti-Human 4‑1BB Ligand/TNFSF9 Monoclonal Antibody (Catalog # MAB22951) at 3 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Sheep HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS019) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: IHC
• Clone: 2357C
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

4-1BB Ligand/TNFSF9 Antibody (2357C) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: E. coli-derived recombinant human 4‑1BB Ligand/TNFSF9
  Arg71-Glu254
  Accession # P41273.1
• Specificity: Detects human 4‑1BB Ligand/TNFSF9 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 3-25 ug/mL
• Control:

  TIM-3 Knockout HeLa Cell Lysate

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for 4-1BB Ligand/TNFSF9 Antibody (2357C) [Unconjugated]

• 41BB Ligand
• 4-1BB Ligand
• 4-1BBL
• 4-1BB-L
• CD137L
• homolog of mouse 4-1BB-L
• receptor 4-1BB ligand
• TNFSF9
• tumor necrosis factor (ligand) superfamily, member 9
• tumor necrosis factor ligand superfamily member 9

Background

4-1BB Ligand (4-1BBL; also CD137L) is a 32 kDa type II transmembrane protein that belongs to the TNF superfamily (TNFSF) molecules (1‑4). The human 4-1BBL cDNA encodes a 254 amino acid (aa) protein that contains a 25 aa N-terminal cytoplasmic domain, a 23 aa transmembrane segment, and a 206 aa C-terminal extracellular region (5). The extracellular domain (ECD) of 4-1BBL has a jelly-roll, beta -sandwich tertiary structure that is similar to other TNFSF members. There is only one cysteine in the human ECD, and no potential N-linked glycosylation sites. The potential exists, however, for O-linked glycosylation. The human 4-1BBL ECD shares 32% and 35% aa identity with mouse and rat ECD, respectively. In the cytoplasmic domain, human 4-1BBL is 55 aa shorter than the equivalent region in rodents. 4-1BBL is expressed by activated B cells, macrophages, dendritic cells, activated T cells, neurons and astrocytes (2, 3, 6). A bioactive 26 kDa soluble form of 4-1BBL, presumably generated by MMP cleavage, occurs in humans (4). Human 4-1BBL signals through both CD137/4-1BB and itself. Its cytoplasmic tail participates in reverse signaling that induces apoptosis in T cells and cytokine secretion (IL-6; TNF-alpha ) by monocytes (7, 8). 4-1BBL binding to CD137/4-1BB produces a number of effects. It seems to play a key role in the T cell recall response. It maintains T cell numbers at the end of a primary response, and induces CD4⁺ and CD8⁺ T cells to proliferate and secrete cytokines such as IL-2 and IFN-gamma in CD4⁺ cells, and IFN-gamma in CD8⁺ cells (9, 10).

1. Kwon, B. et al. (2003) Exp. Mol. Med. 35:8.
2. Salih, H.R. et al. (2002) Int. J. Clin. Pharmacol. Ther. 40:348.
3. Vinay, D.S. and B.S. Kwon (1998) Semin. Immunol. 1:481.
4. Salih, H.R. et al. (2001) J. Immunol. 167:4059.
5. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
6. Reali, C. et al. (2003) J. Neurosci. Res. 74:67.
7. Michel, J. et al. (1999) Immunology 98:42.
8. Langstein, J. et al. (1998) J. Immunol. 160:2488.
9. Wen, T. et al. (2002) J. Immunol. 168:4897.
10. Dawicki, W. and T.H. Watts (2004) Eur. J. Immunol. 34:743.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P41273.1()